Andere talen Algernon Pharmaceuticals Inc.

Aandelen

AGN

CA01559R4008

Beurs gesloten - Canadian Securities Exchange Andere beurzen 21:59:49 03-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,15 ^CAD	-6,25%		-3,23%	+130,77%

30/04	Algernon Pharmaceuticals Inc. rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 29 februari 2024	CI
01/04	Algernon Pharmaceuticals zet onderzoeksprogramma naar psychedelische drug DMT beroerte voort als belangrijkste product	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	01/04
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	27/03
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	27/03
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	25/01
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	24/01
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	29/12
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD	30/11
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	28-07-23
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities	27-06-23
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD	31-05-23
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	02-05-23
Algernon Neuroscience Appoints Dr. David Brody to Advisory Board	21-03-23
Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase	16-02-23
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	30-01-23
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board	11-01-23
Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil	09-01-23
Algernon Pharmaceuticals Inc. Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program	03-01-23
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis	05-12-22
Algernon Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	25-11-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Algernon Pharmaceuticals Inc.

Aandelen

AGN

CA01559R4008

Andere talen

Filters